Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

161. Hepatic Metastasis from Colorectal Cancer (PubMed)

Hepatic Metastasis from Colorectal Cancer The liver is the most common site of metastasis in patients with colorectal cancer due to its anatomical situation regarding its portal circulation. About 14 to 18% of patients with colorectal cancer present metastasis at the first medical consultation, and 10 to 25% at the time of the resection of the primary colorectal cancer. The incidence is higher (35%) when a computed tomography (CT) scan is used. In the last decades, a significant increase (...) in the life expectancy of patients with colorectal cancer has been achieved with different diagnostic and treatment programs. Despite these improvements, the presence of metastasis, disease recurrence, and advanced local tumors continue to remain poor prognostic factors. Median survival without treatment is <8 months from the moment of its presentation, and a survival rate at 5 years of 11% is the best prognosis for those who present with local metastasis. Even in patients with limited metastatic disease

Full Text available with Trip Pro

2017 Euroasian journal of hepato-gastroenterology

162. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme (PubMed)

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme TAS-102 improves overall survival (OS) in patients with metastatic colorectal cancer (mCRC) refractory to standard treatments. However, predictive biomarkers of efficacy are currently lacking.We treated a cohort of 43 chemorefractory mCRC patients treated with TAS-102, in a single institution expanded access

Full Text available with Trip Pro

2017 ESMO open

163. Probiotics as a preventive strategy for surgical infection in colorectal cancer patients: a systematic review and meta-analysis of randomized trials. (PubMed)

Probiotics as a preventive strategy for surgical infection in colorectal cancer patients: a systematic review and meta-analysis of randomized trials. Infection following abdominal surgery remains a major factor in morbidity among colorectal cancer (CRC) patients. Probiotic therapy has been suggested to improve the clinical and laboratory outcome of patients undergoing gastrointestinal surgery. The aim of this study was to investigate the efficacy of probiotic lactic acid bacteria in patients

Full Text available with Trip Pro

2017 Translational gastroenterology and hepatology

164. Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial. (PubMed)

Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial. Increasing participation in fecal screening tests is a major challenge in countries that have implemented colorectal cancer (CRC) screening programs.To determine whether providing general practitioners (GPs) a list of patients who are nonadherent to CRC screening enhances patient participation in fecal

Full Text available with Trip Pro

2017 JAMA

165. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. (PubMed)

Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. Mailed fecal immunochemical test (FIT) outreach is more effective than colonoscopy outreach for increasing 1-time colorectal cancer (CRC) screening, but long-term effectiveness may need repeat testing and timely follow-up for abnormal results.Compare the effectiveness of FIT outreach and colonoscopy outreach to increase completion of the CRC screening

Full Text available with Trip Pro

2017 JAMA

166. Erratum: Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model (PubMed)

Erratum: Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model [This corrects the article DOI: 10.1038/s41540-017-0016-1.].

Full Text available with Trip Pro

2017 NPJ systems biology and applications

167. Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence (PubMed)

Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence Adjuvant chemotherapy has become the standard form of treatment for all patients with stage III colorectal cancer and is also recommended for patients with stage II disease and defined risk factors. However, clinical studies that evaluate the effect of adjuvant treatment regimens have a selection bias in favor of younger patients, so that even retrospective subgroup analyses cannot define the best (...) therapeutic procedure in elderly patients with comorbidities.As long as the role of adjuvant chemotherapy in elderly colorectal cancer patients is not investigated in comprehensive trials, no clear recommendations are possible.An exploratory review of the relevant literature revealed that a formal meta-analysis concerning adjuvant chemotherapy in elderly patients with colorectal cancer is not feasible due to varying definitions of elderly patients, inclusion and exclusion criteria, and a plethora

Full Text available with Trip Pro

2017 Gastrointestinal tumors

168. Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H)

Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides (...) links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic

2017 NIHR Innovation Observatory

169. Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer. (PubMed)

Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer. To investigate the effects of oral zinc supplementation on fatigue intensity and quality of life of patients during chemotherapy for colorectal cancer.A prospective, randomized, double-blinded, placebo-controlled study was conducted with 24 patients on chemotherapy for colorectal adenocarcinoma in a tertiary care public hospital. The study patients received zinc capsules 35mg (Zinc Group, n=10 (...) and fatigue questionnaires were similar between the groups during the chemotherapy cycles. The Placebo Group presented worsening of quality of life and increased fatigue between the first and fourth cycles of chemotherapy, but there were no changes in the scores of quality of life or fatigue in the Zinc Group.Zinc supplementation prevented fatigue and maintained quality of life of patients with colorectal cancer on chemotherapy.Investigar os efeitos da suplementação oral de zinco sobre a intensidade da

Full Text available with Trip Pro

2017 Einstein (Sao Paulo, Brazil)

170. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study (PubMed)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic spindle poisons on BRAF-mutated and BRAF-like CRC models. We designed a phase II trial to test the activity of vinorelbine in patients with BRAF V600E mutated metastatic CRC (mCRC).Patients progressed to or not deemed

Full Text available with Trip Pro

2017 ESMO open

171. Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014 (PubMed)

Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014 28787497 2017 09 20 2018 11 13 1538-3598 318 6 2017 08 08 JAMA JAMA Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years in the United States, 1970-2014. 572-574 10.1001/jama.2017.7630 Siegel Rebecca L RL Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. Miller Kimberly D KD Surveillance and Health Services Research Program, American Cancer (...) Society, Atlanta, Georgia. Jemal Ahmedin A Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. eng Letter United States JAMA 7501160 0098-7484 AIM IM Adult African Americans Age Distribution Colorectal Neoplasms ethnology mortality European Continental Ancestry Group Female Humans Male Middle Aged Mortality trends United States epidemiology Young Adult 2017 8 9 6 0 2017 8 9 6 0 2017 9 21 6 0 ppublish 28787497 2647859 10.1001/jama.2017.7630 PMC5817468 Cancer

Full Text available with Trip Pro

2017 JAMA

172. Age and Outcome in Gastrointestinal Cancers: A Population-Based Evaluation of Oesophageal, Gastric and Colorectal Cancer (PubMed)

Age and Outcome in Gastrointestinal Cancers: A Population-Based Evaluation of Oesophageal, Gastric and Colorectal Cancer With demographic changes and partial representativeness of randomized studies the question arises which results are achieved in the treatment of the elderly. The objective was to analyse population-based data on gastrointestinal cancers in terms of age.Analyses included data of the Munich Cancer Registry, i.e. 4,014, 10,127 and 42,809 invasive oesophageal, gastric (...) and colorectal cancer patients, respectively, which were diagnosed between 1998 and 2014. Tumour characteristics and outcome were analysed by age groups and therapy. Overall survival was analysed using the Kaplan-Meier method, and relative survival was computed as estimation for cancer-specific survival. Additionally, conditional survival of patients surviving at least 6 or 12 months was analysed by age.21, 44 and 38% of oesophageal, gastric and colorectal cancer patients, respectively, were aged >75 years

Full Text available with Trip Pro

2017 Visceral medicine

173. An Unusual Diagnosis in a Patient with Suspected Colorectal Cancer (PubMed)

An Unusual Diagnosis in a Patient with Suspected Colorectal Cancer 29255776 2018 11 13 2341-4545 24 6 2017 Nov GE Portuguese journal of gastroenterology GE Port J Gastroenterol An Unusual Diagnosis in a Patient with Suspected Colorectal Cancer. 308-310 10.1159/000478942 Carmo Joana J Department of Gastroenterology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. Marques Susana S Department of Gastroenterology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa (...) Journal Article 2017 08 04 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Colonic lipoma Colonoscopy Colorectal cancer 2017 03 14 2017 05 18 2017 12 20 6 0 2017 12 20 6 0 2017 12 20 6 1 ppublish 29255776 10.1159/000478942 pjg-0024-0308 PMC5731160 Gastrointest Endosc. 2000 Apr;51(4 Pt 1):495-6 10744833 Gastrointest Endosc. 2003 Sep;58(3):468-70 14528235 World J Gastroenterol. 2007 May 7;13(17):2510-3 17552037

Full Text available with Trip Pro

2017 GE Portuguese journal of gastroenterology

174. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals (...) patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment 2017; 21(33) Authors' objectives To assess the effectiveness of FITs [OC-Sensor (Eiken Chemical Co./MAST Diagnostics, Tokyo, Japan), HM-JACKarc (Kyowa Medex/Alpha Laboratories Ltd, Tokyo, Japan), FOB Gold (Sentinel/Sysmex, Sentinel Diagnostics, Milan, Italy), RIDASCREEN Hb or RIDASCREEN Hb/Hp complex (R-Biopharm, Darmstadt

2017 Health Technology Assessment (HTA) Database.

175. Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54

Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54 1 Translation of addendum A16-77 Trifluridin/Tipiracil (Kolorektalkarzinom) – Addendum zum Auftrag A16-54 (Version 1.0; Status: 13 January 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 13 January 2017 1.0 Commission: A16-77 Version: Status: IQWiG Reports – Commission (...) No. A16-77 Trifluridine/tipiracil (colorectal cancer) – Addendum to Commission A16-54 1 Addendum A16-77 Version 1.0 Trifluridine/tipiracil – Addendum to Commission A16-54 13 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Trifluridine/tipiracil (colorectal cancer) – Addendum to Commission A16-54 Commissioning agency: Federal Joint Committee Commission awarded on: 22 December 2016

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

176. Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V

Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Trifluridin/Tipiracil (Kolorektalkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 November 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A16-54 Trifluridine/tipiracil (colorectal cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A16-54 Version 1.0 Trifluridine/tipiracil (colorectal cancer) 11 November 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Trifluridine/tipiracil (colorectal cancer) – Benefit assessment according to §35a Social Code Book V Commissioning

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

177. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care

Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care Quantitativ Quantitative faecal immunochemical e faecal immunochemical tests to guide referr tests to guide referral for colorectal al for colorectal cancer in primary care cancer in primary care Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) the environmental impact of implementing NICE recommendations wherever possible. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 40Contents Contents 1 Recommendations 4 2 Clinical need and practice 5 The problem addressed 5 The condition 5 The diagnostics and care pathways 6 3 The diagnostic tests 9 The interventions 9

2017 National Institute for Health and Clinical Excellence - Diagnostics Guidance

178. Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test (PubMed)

Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test 28763543 2017 09 07 2018 11 13 1538-3598 318 5 2017 08 01 JAMA JAMA Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test. 483 10.1001/jama.2017.9312 Doubeni Chyke A CA Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia. Corley Douglas A DA Division of Research, Kaiser Permanente Northern California, Oakland. Levin Theodore R (...) TR Division of Research, Kaiser Permanente Northern California, Oakland. eng U54 CA163262 CA NCI NIH HHS United States Letter Comment United States JAMA 7501160 0098-7484 AIM IM JAMA. 2017 Apr 25;317(16):1627-1628 28444260 JAMA. 2017 Aug 1;318(5):483-484 28763547 Colonoscopy Colorectal Neoplasms Early Detection of Cancer Humans Mass Screening Occult Blood 2017 8 2 6 0 2017 8 2 6 0 2017 9 8 6 0 ppublish 28763543 2646711 10.1001/jama.2017.9312 PMC6197858 NIHMS988941 J Comp Eff Res. 2015 Nov;4(6

Full Text available with Trip Pro

2017 JAMA

179. Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment (PubMed)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment To investigate the potential predictors of response to regorafenib, in chemorefractory metastatic colorectal cancer (mCRC) patients with long-term efficacy from regorafenib treatment.Retrospective, single institution analysis of patients with chemorefractory mCRC treated with regorafenib, in clinical practice setting. 123 patients were treated

Full Text available with Trip Pro

2017 ESMO open

180. Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer (PubMed)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer 29303156 2019 01 30 2059-7029 2 3 2017 ESMO open ESMO Open Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. e000205 10.1136/esmoopen-2017-000205 Prager Gerald G Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University Vienna, Vienna, Austria. Argilés Guillem G Vall d'Hebrón Institut of Oncology (VHIO), Vall d'Hebrón University

Full Text available with Trip Pro

2017 ESMO open